A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance

Cancer Medicine

Volumn 6, Issue 1, 2017, Pages 154-162

  Wang, Wenxian ^a   Song, Zhengbo ^a   Zhang, Yiping ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

Author keywords

ARMS; ddPCR; EGFR TKI; non small cell lung cancer; T790M

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ICOTINIB; CROWN ETHER; DIAGNOSTIC KIT; DNA; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AMPLIFICATION REFRACTORY MUTATION SYSTEM ASSAY KIT; ANALYTICAL EQUIPMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CIRCULATING TUMOR CELL; CLINICAL OUTCOME; CONTROLLED STUDY; DROPLET DIGITAL PCR ASSAY KIT; EGFR T790M GENE; EXON; FEMALE; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY DEVICE; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; BLOOD; DIAGNOSTIC KIT; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PRECISION MEDICINE; PROGNOSIS; QUINAZOLINES; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85007403075     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.978     Document Type: Article

References (43)

1. Rosell, R., E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, et al. 2012. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246.
2. Zhou, C., Y. L. Wu, G. Chen, J. Feng, X. Q. Liu, C. Wang et al. 2011. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742.
3. Mitsudomi, T., S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, et al. 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
4. Fukuoka, M., Y. L. Wu, S. Thongprasert, P. Sunpaweravong, S. S. Leong, V. Sriuranpong, et al. 2011. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29:2866–2874.
5. Maemondo, M., A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, et al. 2010. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362:2380–2388.
6. Miller, V. A., V. Hirsh, J. Cadranel, Y. M. Chen, K. Park, S. W. Kim, et al. 2012. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13:528–538.
7. Sequist, L. V., J. C. Yang, N. K. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, et al. 2013. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31:3327–3334.
8. Wu, Y. L., C. Zhou, C. P. Hu, J. Feng, S. Lu, Y. Huang, et al. 2014. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15:213–222.
9. Cataldo, V. D., D. L. Gibbons, R. Perez-Soler, and A. Quintás-Cardama 2011. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364:947–955.
10. Rosell, R., T. G. Bivona, and N. Karachaliou. 2013. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720–731.
11. Yu, H. A., M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski, W. Pao, et al. 2013. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19:2240–2247.
12. Aparicio, S., and C. Caldas. 2013. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368:842–851.
13. Gerlinger, M., A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883–892.
14. de Bruin, E. C., N. McGranahan, R. Mitter, M. Salm, D. C. Wedge, L. Yates, et al. 2014. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256.
15. Zhang, J., J. Fujimoto, J. Zhang, D. C. Wedge, X. Song, J. Zhang, et al. 2014. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256–259.
16. Leary, R. J., M. Sausen, I. Kinde, N. Papadopoulos, J. D. Carpten, D. Craig, et al. 2012. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4:154–162.
17. Chan, K. C., P. Jiang, Y. W. Zheng, G. J. Liao, H. Sun, J. Wong, et al. 2013. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59:211–224.
18. Punnoose, E. A., S. Atwal, W. Liu, R. Raja, B. M. Fine, B. G. Hughes, et al. 2012. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase ii clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18:2391–2401.
19. Luo, J., L. Shen, and D. Zheng. 2014. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci. Rep. 4:6269.
20. Kuang, Y., A. Rogers, B. Y. Yeap, L. Wang, M. Makrigiorgos, K. Vetrand, et al. 2009. Noninvasive detection of EGFR T790m in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15:2630–2636.
21. Sakai, K., A. Horiike, D. L. Irwin, K. Kudo, Y. Fujita, A. Tanimoto, et al. 2013. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 104:1198–1204.
22. Maheswaran, S., L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, et al. 2008. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359:366–377.
23. Sorensen, B. S., L. Wu, W. Wei, J. Tsai, B. Weber, E. Nexo, et al. 2014. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120:3896–3901.
24. Jackman, D., W. Pao, G. J. Riely, J. A. Engelman, M. G. Kris, P. A. Jänne, et al. 2010. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28:357–360.
25. Yang, J. J., H. J. Chen, H. H. Yan, X. C. Zhang, Q. Zhou, J. Su, et al. 2013. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 79:33–39.
26. Kobayashi, S., T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher, M. Meyerson, et al. 2005. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:786–792.
27. Balak, M. N., Y. Gong, G. J. Riely, R. Somwar, A. R. Li, M. F. Zakowski, et al. 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12:6494–6501.
28. Oxnard, G. R., M. F. Paweletz, Y. Kuang, S. L. Mach, A. O'Connell, M. M. Messineo, et al. 2014. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20:1698–1705.
29. Qin, L., W. Zhong, L. Zhang, L. Y. Li, and M. Z. Wang, 2011. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin. Med. J. (Engl). 124:887–891.
30. Oxnard, G. R., M. E. Arcila, C. S. Sima, G. J. Riely, J. Chmielecki, M. G. Kris, et al. 2011. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res. 17:1616–1622.
31. Hata, A., N. Katakami, H. Yoshioka, J. Takeshita, K. Tanaka, S. Nanjo, et al. 2013. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer 119:4325–4332.
32. Li, W., S. Ren, J. Li, A. Li, L. Fan, X. Li, et al. 2014. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 84:295–300.
33. Zheng, D., X. Ye, M. Z. Zhang, Y. Sun, J. Y. Wang, J. Ni, et al. 2016. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci. Rep. 12:20913.
34. Mok, T. S., Y. L. Wu, J. S. Lee, C. J. Yu, V. Sriuranpong, et al. 2015. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer Res. 21:3196–3203.
35. Wang, Z., R. Chen, S. Wang, J. Zhong, M. Wu, J. Zhao, et al. 2015. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS ONE 9:e110780.
36. Ma, M., C. Shi, J. Qian, J. Teng, H. Zhong, and B. Han. 2016. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer. Gene 591:58–64.
37. Hindson, C. M., J. R. Chevillet, H. A. Briggs, E. N. Gallichotte, I. K. Ruf, B. J. Hindson, et al. 2013. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10:1003–1005.
38. Thress, K. S., R. Brant, T. H. Carr, S. Dearden, S. Jenkins, H. Brown, et al. 2014. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of technologies to support the clinical development of AZD9291. J. Clin. Oncol. 9:509–515
39. Takahama, T., K. Sakai, M. Takeda, K. Azuma, T. Hida, M. Hirabayashi, et al. 2016. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget 7:58492–58499. doi: 10.18632/oncotarget.11303.
40. Lee, Y., G. K. Lee, Y. S. Lee, W. Zhang, J. A. Hwang, B. H. Nam, et al. 2014. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer 120:2090–2098.
41. Park, K., C. M. Tsai, M. J. Ahn, C. J. Yu, S. W. Kim, V. Sriuranpong, et al. 2012. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl. 15) [Abstr TPS7614], http://meetinglibrary.asco.org/content/96347-114.
42. Soria, J. C., Y. L. Wu, K. Nakagawa, S. W. Kim, J. J. Yang, M. J. Ahn, et al. 2015. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 16:990–998.
43. Greig, S. L. 2016. Osimertinib: First Global Approval. Drugs 76:263–273.